Skip to main content

Year: 2024

Innventure, Inc. to Announce Third Quarter 2024 Results on November 14

ORLANDO, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) — Innventure, Inc. (Nasdaq: INV) (“Innventure”), a technology commercialization platform, today announced it will release its third quarter 2024 financial results before market open on Thursday, November 14, 2024. Management will host a conference call on the day of the release (November 14, 2024) at 8:30 am ET to discuss the results. The event will be webcasted live via our investor relations website https://ir.innventure.com/ or via this link. Parties interested in joining via teleconference can register using this link: https://register.vevent.com/register/BIc433d3bf08f34d37b56270335fc659fe    After registering, you will be provided dial in details and a unique dial-in PIN. Registration is open through the live call, but to ensure you are connected for the full call, we suggest registering...

Continue reading

Intellia Therapeutics Announces Two Upcoming Investor Events in November 2024

Third quarter 2024 financial results – November 7, at 8 a.m. ET New clinical data from the Phase 1 study of nexiguran ziclumeran (nex-z) for the treatment of transthyretin (ATTR) amyloidosis – November 16, at 11 a.m. CT / 12 p.m. ETCAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced it will be hosting two virtual investor events in November. Third Quarter 2024 Earnings – November 7, at 8 a.m. ETIntellia will present its third quarter 2024 financial results and operational highlights.To join the call, U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726 approximately five minutes before the call. All participants should...

Continue reading

OptimizeRx Sets Third Quarter 2024 Conference Call for November 13, 2024 at 4:30 p.m. ET

WALTHAM, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) — OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, will hold a conference call on Wednesday, November 13, 2024, at 4:30 p.m. Eastern Time to discuss its results for the third quarter period ended September 30, 2024. The financial results will be issued in a press release prior to the call. OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found below:   Date: Wednesday, November 13, 2024Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)Toll Free: 1-844-825-9789International: 1-412-317-5180Conference ID: 10193688Call Me Link: https://callme.viavid.com/?$Y2FsbG1lPXRydWUmcGFzc2NvZGU9JmluZm89Y29tcGFueSZyPXRydWUmYj0xNg==Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1693210&tp_key=d77879d241   Please...

Continue reading

Tourmaline Bio to Present at Upcoming Investor Conferences

NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) — Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer, is expected to participate in the following investor conferences: Truist Securities BioPharma Symposium, New YorkPanel: Close to Heart: Innovative Approaches to Targeting Cardiac & Skeletal Muscle IllnessesThursday, November 7, 2024 at 2:35 pm ET Guggenheim Securities Healthcare Innovation Conference, BostonFireside ChatTuesday, November 12, 2024 at 1:30 pm ET Live webcasts and replays, when available, will be available under “Events and Presentations” in the News...

Continue reading

Kura Oncology to Report Third Quarter 2024 Financial Results

SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report third quarter 2024 financial results after the close of U.S. financial markets on Thursday, November 7, 2024. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing (800) 225-9448 for domestic callers and (203) 518-9708 for international callers and entering the conference ID: KURAQ3. A live webcast and archived replay of the event will be available here or online from the investor relations section of the company website at www.kuraoncology.com. About...

Continue reading

Bombardier Defense Proudly Delivers Eighth Global Aircraft to the U.S. Air Force Battlefield Airborne Communications Node Program

Rendering of the BACN 8 aircraftBombardier Defense delivered the eighth Bombardier Global aircraft to the United States Air Force for the Battlefield Airborne Communications Node (BACN) program at the company’s service centre in Hartford, Connecticut Bombardier’s multi-year agreement with the Air Force supports a distinctive and reliable airborne communications platform that is essential for completing critical missions across air, space, land and sea Due to their proven reliability, endurance, reduced maintenance costs and fuel efficiency, Global business jets have become the go-to platforms for specialized missions around the worldMONTRÉAL, Oct. 31, 2024 (GLOBE NEWSWIRE) — Bombardier Defense today announced the delivery of the eighth Bombardier Global jet to the United States Air Force’s (USAF) BACN program, which is part...

Continue reading

Scorpius Holdings Announces Implementation of New Cost Savings Measures Expected to Save Over $2 Million Annually

Efficiency Initiatives Designed to Accelerate Path to Profitability DURHAM, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) — Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or the “Company”), an integrated biomanufacturing company, today announced the implementation of strategic cost-saving measures expected to save over $2 million annually. The recently implemented measures include the divestiture of certain non-core assets and the initiation of programs designed to optimize operational efficiency across the organization. The Company expects these measures to significantly enhance its financial position and enable a sharper focus on high-margin growth areas within its sales pipeline. “We’re committed to accelerating our path to profitability and achieving positive cash flow through disciplined cost management and operational efficiency,”...

Continue reading

Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024

Company will host conference call at 4:30 p.m. ET that day CELEBRATION, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the treatment of rare diseases, today announced it will report third quarter financial results and provide a corporate update on Tuesday, Nov. 12, 2024. The Company will issue a news release after the market closes and host a conference call/audio webcast at 4:30 p.m. ET that day. The corporate update will include recent progress with the commercial launches of MIPLYFFA™ and OLPRUVA® as well as the Company’s clinical stage programs. A link to the audio webcast will be accessible on the “Events & Presentations” page in the Investor Relations section of Zevra’s website at https://investors.zevra.com/. To...

Continue reading

SIGA to Host Business Update Call on November 7 Following Release of Third-Quarter 2024 Financial Results

NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) — SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, November 7, 2024. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company’s website at http://www.siga.com in the Investor Relations section of the site, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time. Participants may access the call by dialing 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers. A replay of the call will be available for two weeks by dialing 1-844-512-2921...

Continue reading

InHouse by MariMed Launches Help on the Homefront, to Support Veterans Facing Housing Challenges

Local Veterans in Maryland, Massachusetts, Delaware, and Illinois Can Enter to Win $5,000 to Help Offset the Cost of Housing or Home Improvements this November NORWOOD, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) — InHouse™, MariMed’s (“MariMed”) (CSE: MRMD) (OTCQX: MRMD) high quality, value-priced line of flower, vapes, and gummies, is committed to serving local communities by finding ways to provide support to those in need. The mission continues this November with the brand’s latest philanthropic initiative, Help on the Homefront, a program designed to bring awareness to the housing challenges faced by our veterans across the country. Through Help on the Homefront, InHouse will provide $5,000 to a veteran in several of its retail markets, including Maryland, Massachusetts, Delaware, and Illinois. The award is intended to offset...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.